Literature DB >> 8473325

Identification of a new cell adhesion motif in two homologous peptides from the COOH-terminal cell binding domain of human thrombospondin.

M D Kosfeld1, W A Frazier.   

Abstract

Thrombospondin-1 (TS1) contains at least four domains that support cell attachment. The COOH-terminal cell binding domain (CBD) was first identified with a monoclonal antibody against TS1 that blocked secretion-dependent platelet aggregation. Subsequently, this domain of TS1 has been found to bind a number of normal and transformed cells. We have localized attachment sites for human melanoma cells (G361) within the CBD to two noncontiguous 30-residue peptides designated C4 and C7 (Kosfeld, M. D., and Frazier, W. A. (1991) J. Biol. Chem. 267, 16230-16236). Here we report studies to define the active sequences within C4 and C7. An octapeptide, RFYVVMWK (4N1-1), from C4 and a pentapeptide, IRVVM (7N3-1), from C7 were found to support attachment of G361 melanomas, K562 erythroleukemia cells, HT1080 fibrosarcomas, C32 amelanotic melanomas, and endothelial cells. These peptides also inhibit the adhesion of cells to the recombinant CBD of TS1. The hexapeptide RFYVVM (4N1-2) also inhibits cell attachment. The inhibitory effect of combinations of C4- and C7-derived peptides is synergistic. The sequences 4N1-1 and 7N3-1 of TS1 share homology with two cell adhesive peptides from laminin (LM), LMF9 and LMPA22-2, respectively. These TS1 and LM peptides are interchangeable in inhibiting the adhesion of G361 cells to LM or TS1, suggesting a possible sharing of receptors by LM and TS1. K562 cells, however, bound only to TS1, and this binding was inhibited preferentially by the TS1 CBD peptides, indicating a receptor specific for TS1 which does not recognize LM. The active TS1 peptides are highly conserved among five species and four isoforms of TS1. Homologs of the TS1 peptides are found in tenascin, a matrix protein that shares several properties with TS1 and in factor VIII, alpha 2-macroglobulin, and von Willebrand factor.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8473325

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

Review 1.  CD47: a new target in cardiovascular therapy.

Authors:  Jeff S Isenberg; David D Roberts; William A Frazier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-10       Impact factor: 8.311

2.  Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1.

Authors:  P Clezardin; J Lawler; J Amiral; G Quentin; P Delmas
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

3.  Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease.

Authors:  Stéphane M Camus; João A De Moraes; Philippe Bonnin; Paul Abbyad; Sylvain Le Jeune; François Lionnet; Laurent Loufrani; Linda Grimaud; Jean-Christophe Lambry; Dominique Charue; Laurent Kiger; Jean-Marie Renard; Claire Larroque; Hervé Le Clésiau; Alain Tedgui; Patrick Bruneval; Christina Barja-Fidalgo; Antigoni Alexandrou; Pierre-Louis Tharaux; Chantal M Boulanger; Olivier P Blanc-Brude
Journal:  Blood       Date:  2015-03-31       Impact factor: 22.113

4.  Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium.

Authors:  Natalya V Narizhneva; Olga V Razorenova; Eugene A Podrez; Juhua Chen; Unni M Chandrasekharan; Paul E DiCorleto; Edward F Plow; Eric J Topol; Tatiana V Byzova
Journal:  FASEB J       Date:  2005-04-15       Impact factor: 5.191

5.  Targeting chronic lymphocytic leukemia with N-methylated thrombospondin-1-derived peptides overcomes drug resistance.

Authors:  Elodie Pramil; Linda Herbi Bastian; Thomas Denèfle; Fariba Nemati; Malina Xiao; Eva Lardé; Karim Maloum; Damien Roos-Weil; Elise Chapiro; Magali Le Garff-Tavernier; Frédéric Davi; Didier Decaudin; Marika Sarfati; Florence Nguyen-Khac; Hélène Merle-Béral; Philippe Karoyan; Santos A Susin
Journal:  Blood Adv       Date:  2019-10-22

6.  T-cell regulation through a basic suppressive mechanism targeting low-density lipoprotein receptor-related protein 1.

Authors:  Jeneen Panezai; Eva Bergdahl; Karl-Gösta Sundqvist
Journal:  Immunology       Date:  2017-07-10       Impact factor: 7.397

7.  Muskelin, a novel intracellular mediator of cell adhesive and cytoskeletal responses to thrombospondin-1.

Authors:  J C Adams; B Seed; J Lawler
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

8.  Kaposi's sarcoma in an HIV-negative CLL patient as the cause of thrombocytopenia.

Authors:  P W Wijermans; K van Groningen; E A van Royen; J A Bruijn
Journal:  Ann Hematol       Date:  1994-06       Impact factor: 3.673

9.  Identification of Isthmin 1 as a Novel Clefting and Craniofacial Patterning Gene in Humans.

Authors:  Lisa A Lansdon; Benjamin W Darbro; Aline L Petrin; Alissa M Hulstrand; Jennifer M Standley; Rachel B Brouillette; Abby Long; M Adela Mansilla; Robert A Cornell; Jeffrey C Murray; Douglas W Houston; J Robert Manak
Journal:  Genetics       Date:  2017-11-21       Impact factor: 4.562

10.  Thrombospondins function as regulators of angiogenesis.

Authors:  Paul Bornstein
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.